Form 4: Akero Therapeutics Executive Patrick Lamy Reports Stock Acquisition

Senior VP of Commercial Strategy at Akero Therapeutics, Patrick Lamy, reports acquiring 221 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, reported acquiring 221 shares of common stock on June 28, 2024.
• The shares were purchased through the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan.
• The purchase price was $19.941 per share, representing 85% of the closing price of Akero Therapeutics' common stock on the transaction date.
• Following the transaction, Mr. Lamy directly owns 18,783 shares of Akero Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects an executive's investment in the company, which can be seen as a sign of confidence. However, it's a routine transaction and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• Executive's participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.
• The acquisition increases the executive's stake in the company, aligning his interests with those of shareholders.

Future Outlook

No forward-looking statements are provided in this document.

Industry Context

This filing is a routine disclosure of insider stock transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their investment decisions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company executive.

Key Dates